Introduction {#s1}
============

Alternative splicing generates gene function complexity in many neural developmental processes, including neuronal differentiation, neuronal migration, axon growth and guidance, and synapse formation and function ([@bib24]; [@bib39]; [@bib42]). A large number of axon guidance molecules undergo alternative splicing, including *Dscam* ([@bib66]), *Netrin* ligands and their *Dcc* and *Neogenin* receptors ([@bib33]; [@bib60]; [@bib83]), *Slit* ligands and *Robo* receptors ([@bib6]; [@bib9]; [@bib10]; [@bib14]; [@bib44]; [@bib72]), *Semaphorin* ligands and *Neuropilin* and *Plexin* receptors ([@bib5]; [@bib13]; [@bib58]; [@bib70]; [@bib71]), and *Ephrins* and *Ephs* ([@bib26]; [@bib38]; [@bib64]). However, the functional significance of these alternative splicing events and the splicing factors responsible for generating protein variants for these molecules remain largely uncharacterized.

*Netrin* and *Dcc* (deleted in colorectal carcinoma) function during cell migration, neurite specification and growth, axon guidance, synaptogenesis, and tumorigenesis ([@bib12]; [@bib35]; [@bib51]; [@bib52]). Within the spinal cord commissural neurons, DCC is required for Netrin-stimulated axon outgrowth and for attracting the axons to the Netrin-secreting midline ([@bib18]; [@bib17]; [@bib20]). Mammalian *Dcc* undergoes alternative splicing to generate two isoforms that differ in the extracellular domain, in the linker sequence between the fourth and fifth fibronectin repeats (FN4 and FN5) ([@bib60]). This alternative splicing was first reported in neuroblastoma cells and was found to be disrupted in these tumor cells ([@bib60]), but its physiological significance was completely unknown. We refer to the splice variants hereafter as DCC~long~ and DCC~short~, with DCC~long~ containing extra 20 amino acids in the FN4-FN5 linker. Interestingly, a recent structure study shows that the two isoforms bind Netrin-1 with comparable affinities, but are likely to adopt distinct conformations upon ligand binding ([@bib76]).

To reveal the factors that control the alternative splicing of axon guidance genes including *Dcc*, we carried out an in vivo RNAi screen against candidate RNA-binding proteins (RBPs) in cultured mouse embryos, and found that *Nova1* and *Nova2* knockdown leads to severe defects in the dorsal spinal cord interneurons, including the commissural interneurons. The NOVA (neuro-oncological ventral antigen) proteins were first identified as the autoimmune antigens in the neurodegenerative disease POMA (paraneoplastic opsoclonus myoclonus ataxia; [@bib15]). NOVA1/2 are neural-specific KH (hnRNP K homology)-type of RBPs that can directly regulate alternative splicing ([@bib4]; [@bib41]; [@bib75]). Genome-wide studies have identified many potential NOVA targets that are involved in various neural developmental processes ([@bib43]; [@bib74]; [@bib82]). In vivo studies using *Nova* knockout mice have demonstrated defects in synapse formation and function, and in neuronal migration ([@bib28]; [@bib31]; [@bib61]; [@bib77]).

We show here that *Nova1/2* loss of function reduces the migration of the spinal cord interneurons and their progenitors, and disturbs the axon outgrowth and guidance of the commissural interneurons. Interestingly, these defects resemble those seen in *Dcc* knockouts. Consistently, *Dcc* alternative splicing is perturbed by *Nova* deficiency in vivo. Through rescue experiments, we show that restoring *Dcc~long~*, the diminished isoform in *Nova* knockouts, is able to reverse the defects. Furthermore, NOVA1/2 regulate *Dcc* pre-mRNA splicing in in vitro assays. Together, our results demonstrate that *Dcc* alternative splicing is important for the gene function and is controlled by the NOVA splicing factors.

Results {#s2}
=======

An in vivo RNAi screen to identify RBPs involved in axon guidance {#s2-1}
-----------------------------------------------------------------

Using the whole mouse embryo culture technique ([@bib9]), we transiently knocked down candidate RBPs with small interference RNAs (siRNAs) in the spinal cord and examined the resulting phenotype in commissural axon guidance. We selected RBPs that have neural-specific expression and have been implicated in alternative splicing ([Table 1](#tbl1){ref-type="table"}). The list of candidates is not exhaustive, and the screening against additional RBPs is ongoing. Some of the RBPs, including NOVA, FOX, and PTBP2/nPTB, directly regulate splicing by recognizing specific sequences in pre-mRNAs and controlling spliceosome assembly ([@bib1]; [@bib42]). Some, such as CELF, UPF, and IGF2BP1, play an indirect role, often by regulating the stability of selective pre-mRNAs and thus influencing their splicing ([@bib1]; [@bib37]; [@bib42]; [@bib79]). Others, such as ELAVL/HU, can have both direct and indirect effects on alternative splicing ([@bib1]; [@bib42]; [@bib65]; [@bib30]).10.7554/eLife.14264.003Table 1.RNA-binding proteins targeted in the RNAi screen**DOI:** [http://dx.doi.org/10.7554/eLife.14264.003](10.7554/eLife.14264.003)GeneProtein familyPhenotypeNote*Nova1/2*Neuro-oncological ventral antigenNeuronal migration, axon outgrowth, and axon guidance defects Ptbp2Polypyrimidinetract-binding protein- SfpqSplicing factor proline/glutamine rich (polypyrimidine tract-binding protein associated)- *Fmr1*Fragile X mental retardation protein- *Nufip1/2*Nuclear FMRP interacting protein- *Elavl1/2/3/4*ELAV (embryonically lethal abnormal vision) homolog; Hu syndrome proteinPartial midline crossing defect caused by *Elavl2* single RNAi *Rbfox1/2/3*RNA-binding protein, Fox (feminizing locus on X) homolog- *Msi1 *Musashi RNA-binding protein-*Msi1-/-* displays neuronal migration and axon guidance defects in precerebellar neurons but not in spinal commissural neurons ([@bib36]*Upf1 *UPF1 regulator of nonsense transcripts homolog Neuronal migration, axon outgrowth, and axon guidance defects *Celf1/2/3/4/5/6*CUG binding protein, Elav-like family member- *Khsrp*KH-type splicing regulatory protein- *Pabpc1*Poly(A) binding protein, cytoplasmic- *Igf2bp1*Insulin-like growth factor 2 mRNA binding proteinPartial midline crossing defectRegulates *beta-actin* mRNA transport and translation ([@bib40]; [@bib78])*Srpk1/2*Serine/arginine-rich protein specific kinase- -, no phenotype in spinal cord commissural neurons, when family members were targeted individually.

Using electroporation, we introduced siRNAs and *gfp* into the neural progenitors adjacent to the lumen of the neural tube ([Figure 1A](#fig1){ref-type="fig"}). We observed that the dorsal interneuron progenitors are mostly targeted, whereas the ventral motor neuron progenitors are not ([@bib9]; [Figure 1B](#fig1){ref-type="fig"}). This is likely due to the fact that the dorsal progenitors are more actively proliferating and differentiating during the culture period. We used *Actb*-gfp (aka *βactin-gfp*) in order to label the highly heterogeneous populations of commissural neurons, which are mostly descended from the dorsal progenitors. Following electroporation, the mitotic neuroprogenitors migrate laterally away from the ventricle ([@bib7]; [@bib25]; [@bib45]). Upon neural differentiation around E10 in mice, the progenitors exit the cell cycle and migrate out of the ventricular zone (VZ) to reach the lateral spinal cord. Differentiated interneurons, including commissural and ipsilateral-projecting neurons continue to migrate laterally and different subpopulations also migrate dorsally or ventrally to reach their final positions. Mature commissural neurons then grow out axons and project them toward and across the ventral midline ([@bib7]; [@bib25]; [@bib45]; [Figure 1A](#fig1){ref-type="fig"}).10.7554/eLife.14264.004Figure 1.*Nova1/2* loss of function disrupts the development of dorsal spinal cord interneurons.(**A**) Schematic of neural development in the dorsal spinal cord during whole embryo culture. Nucleotides are microinjected and electroporated into neural progenitors at the superficial layer of the ventricular zone (VZ, outlined by dashed lines). We observed that the dorsal interneuron progenitors are mostly targeted whereas the ventral motor neuron progenitors are not. The dorsal interneuron progenitors migrate laterally and exit the VZ to differentiate into commissural and ipsilateral interneurons. These interneurons continue to migrate laterally as well as along the dorsoventral axis. Mature commissural neurons extend axons to and across the ventral midline. (**B**) Transverse sections of spinal cords electroporated with control or pan-*Nova* siRNAs, and sections from wildtype (WT), *Nova* double knockout (dKO), and *Dcc* KO. *Actb-gfp* was used to label the highly heterogeneous interneuron populations. *Nova* and *Dcc* deficiency leads to an increased number of neuroprogenitors in the VZ (asterisk), and fewer and shorter ventrally-projecting axons (arrow). Bracket, the ventral midline. (**C**) Quantification of phenotypes in B. Neuroprogenitors in the VZ is quantified as the ratio between the signal from the medial spinal cord (boxed area 1) to that from the lateral spinal cord (area 2). Axon ventral projection is quantified as the ratio between the signal from axons that have reached the ventral margin (area 3) and that from the beginning of the axon shaft (area 4). For quantification of phenotypes in all experiments, if *Nova* WT and dKO were not littermates, they were first normalized to the respective double heterozygous (dHet) littermates, and were then compared with each other. *Dcc* KOs were compared with WT littermate controls. Also see [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"} for additional quantification. Data are represented as the mean ± SEM (Student's t-test, \*p\<0.05, \*\*p\<0.001). Scale bar, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.004](10.7554/eLife.14264.004)10.7554/eLife.14264.005Figure 1---source data 1.Quantification of neuronal migration and axon projection phenotypes in cultured embryos.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.005](10.7554/eLife.14264.005)10.7554/eLife.14264.006Figure 1---figure supplement 1.RNAi phenotypes of candidate RNA-binding proteins.(**A**) Transverse sections of spinal cords treated with control, pan-*Nova*, and *Upf1* siRNAs. The latter two siRNA treatments cause defects in progenitor migration and commissural axon ventral projection (indicated with asterisk and arrow, respectively). Also see [Figure 1](#fig1){ref-type="fig"} for *Nova* RNAi effect. (**B**) Openbook preparation of spinal cords treated with control, *Elavl2*, and *Igf2bp1* siRNAs. Neurons electroporated with *gfp* and siRNAs are orientated to the left, and their axons project to and across the midline (bracket). *Elavl2* and *Igf2bp1* knockdown causes some commissural axons to abnormally remain on the ipsilateral side (indicated with arrow). Scale bars, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.006](10.7554/eLife.14264.006)10.7554/eLife.14264.007Figure 1---figure supplement 2.*Nova* and *Dcc* KOs cause axon projection defect.(**A**) *Atoh1-gfp* was used to label the dorsal most dI1 population of interneurons and their progenitors. *Nova* and *Dcc* KO axons are shorter and fail to reach the midline (bracket). (**B**) Quantification of ventral axon projection in A. The distance from the dorsal margin of the spinal cord to the ventral most axons is compared to the total height of the spinal cord (1/2 ratio). Data are normalized to WT and are represented as the mean ± SEM (Student's t-test, \*\*p\<0.001). Also see [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"} for additional quantification. Scale bar, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.007](10.7554/eLife.14264.007)

Among the candidates, knockdown of *Nova1/2, Upf1, Elavl2*, and *Igf2bp1* caused commissural neuron defects ([Figure 1---figure supplement 1](#fig1s1){ref-type="fig"}). *Nova1/2* and *Upf1* knockdown disrupted both neuronal migration and axon projection ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"} and see below). *Elavl2* and *Igf2bp1* knockdown partially blocked commissural axons from crossing the midline ([Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}). Since many RBPs have multiple family members, the lack of effect from other candidates may result from functional redundancy between homologues.

*Nova1/2* loss of function disrupts dorsal interneuron development and resembles *Dcc* knockout {#s2-2}
-----------------------------------------------------------------------------------------------

We found that single knockdown of either *Nova1* or *Nova2* had no effect compared with control siRNAs, but a pan-*Nova* siRNA that targets both homologues caused severe defects ([Figure 1B,C](#fig1){ref-type="fig"}). First, there were an increased number of GFP-positive neurons within the VZ, indicating an abnormality in the interneuron progenitors. Second, there were fewer ventrally projecting axons, which often failed to reach the midline, suggesting a defect in commissural axon growth and/or guidance ([Figure 1B,C](#fig1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}).

To corroborate the RNAi effect, we examined *Nova1/2* knockout (KO) embryos labeled with *Actb-gfp*. We found that neither *Nova1* nor *Nova2* single KOs displayed any defect. However, *Nova1* KO; *Nova2* KO (referred to hereafter as *Nova* dKO) caused the same defects as *Nova1/2* double knockdown ([Figure 1B,C](#fig1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). In addition, *Nova1* Het; *Nova2* KO displayed the same defects, whereas other genotype combinations including *Nova1* KO; *Nova2* Het are phenotypically normal (see below). Thus, *Nova1* and *Nova2* have redundant functions in regulating dorsal interneuron development and *Nova2* appears to play a major role.

The Netrin-DCC signaling is required to stimulate commissural axon outgrowth and to attract the axons to the ventral midline, we thus compared cultured *Dcc* KOs with *Nova* dKOs. Interestingly, we observed the same defects in *Dcc* KOs, namely more GFP+ neurons within the VZ, and shorter and fewer ventrally projecting axons ([Figure 1B,C](#fig1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). We also labeled *Nova* and *Dcc* KOs with *Atoh1-gfp* (aka *Math1-gfp*), which is expressed in the dorsal most dI1 subpopulation of interneurons and their progenitors ([@bib46]). Similarly, we observed a reduction in axon ventral projection in both mutants ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). Due to the small number of neurons being labeled, we could not determine if there are more *Atoh1-gfp* expressing neurons in the VZ in the mutants.

To determine the identity of the ACTB-GFP+ neurons and axons, we immunostained the cultured embryos with neuronal and axonal markers. We used PAX3/7 antibodies to label the dorsal interneuron progenitors that give rise to different populations of commissural and ipsilateral neurons ([@bib7]; [@bib25]). *Pax3* and *Pax7* are required to specify the majority of commissural neurons, as their double knockout greatly reduces the ventral commissure formed by commissural axons crossing the midline ([@bib48]). We labeled differentiated interneurons with antibodies against BARHL2 and LHX5, two transcription factors among many others that are expressed by post-mitotic interneurons. Combinations of these transcription factors define the different lineages of commissural and ipsilateral neurons ([@bib7]; [@bib25]). We also labeled commissural axons specifically with anti-ROBO3 ([@bib63]). Our studies show that the GFP+ neurons within the VZ are dorsal interneuron progenitors and the ones at the lateral spinal cord are differentiated interneurons. In addition, the GFP+ axons that fail to project to the midline are commissural axons ([Figure 2](#fig2){ref-type="fig"}). Furthermore, using fluorescent in situ hybridization, we found that the GFP+ neuroprogenitors and interneurons also express *Dcc* ([Figure 2---figure supplement 1](#fig2s1){ref-type="fig"}), consistent with previous reports that *Dcc* is expressed in these neuronal populations ([@bib34]; [@bib57]). Taken together, *Nova* deficiency appears to disturb commissural axon projection and also interferes with earlier stages of commissural neuron development in the progenitors.10.7554/eLife.14264.008Figure 2.Expression of neuronal and axonal markers in cultured *Nova* WT and dKO embryos electroporated with *Actb-gfp*.PAX3/7 immunostaining labels dorsal interneuron progenitors, which reside within the ventricular zone and give rise to different populations of interneurons. BARHL2 and LHX5 stainings label differentiated interneurons at the lateral spinal cord. ROBO3 staining specifically labels the commissural axons. Scale bar, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.008](10.7554/eLife.14264.008)10.7554/eLife.14264.009Figure 2---figure supplement 1.Fluorescent in situ hybridization of *Dcc* in cultured embryos electroporated with *Actb-gfp*.*Nova* dKO was used as there are more GFP+ neurons in the VZ. *Dcc* expression is seen in GFP+ neuroprogenitors and interneurons. Scale bars, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.009](10.7554/eLife.14264.009)

*Nova* dKO delays neuronal migration but does not affect neuronal differentiation {#s2-3}
---------------------------------------------------------------------------------

The increase in GFP+ neuroprogenitors in the VZ could result from slowed migration, increased proliferation, or reduced neuronal differentiation. To follow cell migration, we electroporated the progenitors with *Actb-gfp* and cultured the embryos for 20 hrs. In WT embryos, we observed that many progenitors have reached the lateral spinal cord after 20 hrs. However, in both *Nova* and *Dcc* KOs, almost all GFP+ neurons are still positioned within the VZ ([Figure 3](#fig3){ref-type="fig"}). This supports the idea that neuronal migration is reduced. We examined cell proliferation in *Nova* and *Dcc* KOs using cell cycle markers, including phospho-histone H3 (pH3), a mitotic marker, and Ki-67, a cell proliferation marker. We found that at E10.5, the number of neural stem cells and progenitors is normal in both mutants ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). In addition, we labeled the neural progenitors in the whole spinal cord with SOX2 and the dorsal progenitors with PAX3/7, and found no change in the localization or organization of these progenitor populations ([Figure 3---figure supplement 1](#fig3s1){ref-type="fig"}). We also examined interneuron differentiation using the BARHL2, ISL1/2, and LHX5 markers, and found that a normal number of interneurons are born in *Nova* and *Dcc* KOs at E10.5 ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}; [Figure 4](#fig4){ref-type="fig"}). Therefore, both *Nova* and *Dcc* deficiency reduces neuroprogenitor migration, but does not affect cell proliferation or interneuron differentiation.10.7554/eLife.14264.010Figure 3.*Nova* and *Dcc* knockouts delay the lateral migration of dorsal interneuron progenitors.*Actb-gfp* was electroporated into neural progenitors and embryos were cultured for 20 hrs. The bottom panel shows the closeup images of the boxed area from the middle panel. Many WT neurons have migrated out of the VZ (demarcated by PAX3/7 staining) after 20 hrs, whereas *Nova* and *Dcc* KO neurons are mostly located within the VZ. Scale bars, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.010](10.7554/eLife.14264.010)10.7554/eLife.14264.011Figure 3---figure supplement 1.Neural stem cells and progenitors appear normal in *Nova* and *Dcc* KOs.(**A**) Immunohistochemistry of phospho-histone H3, a mitotic marker, Ki-67, a cell proliferation marker, SOX2, a neural progenitor marker, and PAX3/7, a dorsal interneuron progenitor marker, in E10.5 spinal cords. (**B**) Quantification of phenotypes in A. pH3+ cells were counted and normalized to WT. The ratio between the SOX2+ VZ area and the total spinal cord area was quantified and normalized to WT. Data are represented as the mean ± SEM (Student's t-test, ns, not significant). Scale bar, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.011](10.7554/eLife.14264.011)10.7554/eLife.14264.012Figure 3---figure supplement 2.Dorsal interneuron differentiation is normal in *Nova* and *Dcc* KOs.(**A**) Immunohistochemistry of ISL1/2 and LHX5 in *Nova* WT, *Nova* dKO, *Dcc* WT, and *Dcc* KO spinal cords at E10.5. The markers are expressed by different subpopulations of interneurons in the dorsal spinal cord. (**B**) Quantification of ISL1/2+ neurons located in the dorsal half of the spinal cord. Data are normalized to WT and are represented as the mean ± SEM (Student's t-test, ns, not significant). Scale bar, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.012](10.7554/eLife.14264.012)10.7554/eLife.14264.013Figure 4.*Nova* and *Dcc* knockouts delay neuronal migration but do not disturb neuronal differentiation.(**A**) Immunohistochemistry of BARHL2 in *Nova* WT, *Nova* dKO, *Dcc* WT, and *Dcc* KO spinal cords. A normal number of BARHL2+ neurons are generated in *Nova* and *Dcc* mutants at E10.5. At E11.75, BARHL2+ neurons fail to arrive at the lateral margin of the spinal cord in the KOs (indicated by arrow). Their ventral migration is also delayed. At E12.5, both dI1i (ipsilateral) and dI1c (commissural) populations appear normal in the mutants. (**B**) Quantification of phenotypes in A. For quantification of the lateral migration, the distance between the lateral margin of the spinal cord and the medial most BARHL2+ neurons are divided into two. The percentage of neurons within each half is shown. For quantification of the ventral migration, the distance from the dorsal margin of the spinal cord to the ventral most BARHL2+ neurons are divided into four. The percentage of neurons within each quarter (1 to 4 from dorsal to ventral) is shown. Three embryos from each genotype and at least five sections from each embryo were quantified. Data are normalized to WT for total neuron number and dI1c/dI1i ratio. Data are represented as the mean ± SEM (Student's t-test for total neuron number, dI1c/dI1i ratio, and lateral migration, \*\*p\<0.001, ns, not significant. Two way ANOVA and Bonferroni post test for ventral migration, \*p\<0.05). Scale bars, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.013](10.7554/eLife.14264.013)

We further examined the migration of post-mitotic interneurons using the BARHL2 marker. *Barhl2* acts downstream of *Atoh1* to specify the dI1 interneurons, including the dI1i (ipsilateral) and dI1c (commissural) populations ([@bib19]; [Figure 4A](#fig4){ref-type="fig"}). DI1 neurons migrate both ventrally and laterally, and dI1i migrates even further laterally than dI1c ([@bib19]). As discussed above, a normal number of BARHL2+ neurons are generated at E10.5 in *Nova* and *Dcc* KOs ([Figure 4](#fig4){ref-type="fig"}). By E11.75, most neurons in WT have migrated ventrally and some start to arrive at the lateral margin of the spinal cord ([@bib19]; [Figure 4](#fig4){ref-type="fig"}). In contrast, there are fewer BARHL2+ neurons at the ventral most and lateral most positions in *Nova* and *Dcc* KOs ([Figure 4](#fig4){ref-type="fig"}), suggesting a reduction in both dorsoventral and mediolateral migration. Later at E12.5, the dI1c and dI1i populations can be well discerned in WT ([@bib19]; [Figure 4A](#fig4){ref-type="fig"}). Similarly, *Nova* and *Dcc* KOs also had two distinct populations of BARHL2+ neurons and the ratio between them is normal ([Figure 4](#fig4){ref-type="fig"}). Therefore, despite a transient delay in the migration, both commissural and ipsilateral neurons are properly specified.

*Nova* dKOs disrupts Netrin-DCC dependent commissural axon outgrowth {#s2-4}
--------------------------------------------------------------------

To understand the defect in commissural axon ventral projection, we examined axon outgrowth in *Nova* dKO using explants of the dorsal spinal cord (DSC). In this assay, commissural axons extend out of the explant in the presence of Netrin-1 after a culture period of 16 hrs ([@bib68]). In the absence of Netrin-1, commissural axons are also able to grow out, but only after an extended period of culturing (after 40 hrs; [@bib34]). We isolated E11.5 DSC from *Nova* dKOs and first tested if commissural neurons are defective in Netrin-stimulated axon outgrowth. Even after 24 hrs in the presence of Netrin-1, when control explants had robust axon outgrowth, *Nova* dKO axons had very little growth ([Figure 5](#fig5){ref-type="fig"}). The same outgrowth defect was also seen in *Dcc* KOs, as previously reported ([@bib76]; [Figure 5](#fig5){ref-type="fig"}).10.7554/eLife.14264.014Figure 5.*Nova* dKO disrupts Netrin-1 induced axon outgrowth in dorsal spinal cord (DSC) explant assays.(**A**) DSC axon outgrowth in *Nova* WT, *Nova* dKO, *Dcc* WT, and *Dcc* KO in the presence or absence of 250 ng/ml Netrin-1. Axons were visualized by rhodamine-phalloidin staining. *Nova* dKO and *Dcc* KO display a drastic reduction in axon growth in response to Netrin. However, both mutants are able to extend axons after an extended culture period in the absence of Netrin. The insets in the bottom panel show no axon outgrowth after 24 hrs of culturing for all genotypes in the absence of Netrin. (**B**) Quantification of axon outgrowth in A. Axon outgrowth is represented as the ratio between the signal from all axons extending out of the explant and that from the cell bodies within the explant, after background extraction. Three embryos from each genotype and at least five explants from each embryo were quantified. Data are normalized to WT and are represented as the mean ± SEM (Student's t-test, \*\*p\<0.001, ns, not significant). Scale bar, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.014](10.7554/eLife.14264.014)10.7554/eLife.14264.015Figure 5---figure supplement 1.Commissural axon outgrowth in *Nova* embryos.(**A**) Cultured dorsal spinal cord explants from nine genotypes. Explants were cultured for 24 hrs in the presence of 250 ng/ml Netrin-1 and axons were labeled with rhodamine-phalloidin. (**B**) Quantification of axon growth in A (normalized to WT). Data are represented as the mean ± SEM (one way ANOVA and Bonferroni post test, \*\*p\<0.001, ns, not significant). Scale bar, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.015](10.7554/eLife.14264.015)

We also examined Netrin-independent axon outgrowth by culturing the explants in the absence of Netrin-1 for 40 hrs ([Figure 5](#fig5){ref-type="fig"}). As expected, we did not observe any axon outgrowth after 24 hrs. However after 40 hrs, there was robust axon outgrowth from both control and *Nova* dKO, and the degree of growth is comparable between the two. In addition, *Dcc* KOs also displayed the same degree of Netrin-independent axon outgrowth ([Figure 5](#fig5){ref-type="fig"}). Therefore, like *Dcc* KOs, *Nova* dKO commissural axons do not have a general growth defect. Rather, they fail to grow in response to Netrin stimulation.

*Nova* dKOs disrupts commissural axon guidance to the midline {#s2-5}
-------------------------------------------------------------

Loss of Netrin-DCC mediated attraction in vivo reduces the number of commissural axons that are able to reach the midline ([@bib21]; [@bib67]; [@bib76]). We thus examined commissural axon guidance to the midline using immunostaining of the axonal markers ROBO3 and TAG-1. We found that at E10.5 and E11.5, the intensity of these axonal markers from the ventral half of the spinal cord was significantly reduced in *Nova* dKOs, suggesting a reduction of ventral axon projection ([Figure 6](#fig6){ref-type="fig"}). At E11.5, there are usually two main commissural axon bundles. Both are reduced in *Nova* dKOs and the more lateral one is more profoundly affected. The size of the ventral commissure, formed by axons crossing the midline, is also reduced ([Figure 6](#fig6){ref-type="fig"}). By E12.5, the reduction in the commissure size is still significant but is somewhat alleviated than at earlier stages. A similar reduction in axons reaching and crossing the ventral midline is also seen in *Dcc* KOs ([@bib21]; [@bib76]). The severity of the defect is similar between *Nova* and *Dcc* mutants ([Figure 6](#fig6){ref-type="fig"}). One distinction between the two mutants is that *Dcc* KO axons are defasciculated and often invade the motor column ([@bib76]), whereas such a defect was not observed in *Nova* dKOs ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}).10.7554/eLife.14264.016Figure 6.*Nova* dKO disrupts commissural axon ventral projection.(**A**) and (**B**) Immunohistochemistry of commissural axonal markers, ROBO3 and TAG-1 respectively, in transverse sections of the spinal cord. Two main axon bundles can be observed at E11.5 (arrows) and the more lateral one is severely reduced in *Nova* dKOs. In the top panel of B, arrows indicate commissural axon projection, and the staining in the ventral lateral spinal cord is from motor axons. (**C**) Quantification of axon guidance phenotypes in A. To quantify axon ventral projection, the signal from the ventral half of the spinal cord was first normalized to the signal from the whole spinal cord, and then normalized to WT controls. The commissure size is represented as the ratio between the thickness of the axon bundle at the midline and that of the floorplate. Data are normalized to WT. Three embryos from each genotype and at least five sections from each embryo were quantified. Data are represented as the mean ± SEM (Student's t-test, \*p\<0.05, \*\*p\<0.001). Scale bars, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.016](10.7554/eLife.14264.016)10.7554/eLife.14264.017Figure 6---figure supplement 1.*Nova* dKO does not cause commissural axons to invade the motor column.(**A**) Immunohistochemistry of ROBO3 in *Nova* WT, *Nova* dKO, *Dcc* WT, and *Dcc* KO spinal cords. Only the ventral half is shown (MC, motor column). Some commissural axons in *Dcc* KO, but not in *Nova* dKO, are defasciculated and invade the motor column (arrows). (**B**) Quantification of phenotypes in A. The amount of commissural axons in the motor column is represented as the ratio between the ventral area covered by commissural axons and that of the total ventral area. Data are normalized to WT and are represented as the mean ± SEM (Student's t-test, \*p\<0.05, ns, not significant). Scale bar, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.017](10.7554/eLife.14264.017)

Besides Netrin, SHH (sonic hedgehog) and VEGF (vascular endothelial growth factor) have also been shown to attract commissural axons ([@bib8]; [@bib62]). However, the loss of SHH or VEGF and their receptors in vivo does not lead to a significant reduction of the ventral commissure ([@bib8]; [@bib54]; [@bib62]). SHH and VEGF also do not induce commissural axon outgrowth in the DSC assay, and their deficiency does not affect commissural axon outgrowth in vivo. Taken together, our results show that *Nova* loss of function disrupts Netrin-DCC signaling during commissural axon outgrowth and guidance.

*Nova* dKO disrupts *Dcc* alternative splicing {#s2-6}
----------------------------------------------

To determine if the Netrin-DCC pathway is affected on the molecular level, we set out to examine the expression and alternative splicing of the pathway components. Using in situ hybridization, we found that *Nova1* and *Nova2* are highly expressed in commissural neurons, but not in the floorplate, where Netrin is expressed ([Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). This expression pattern as well as the fact that isolated *Nova* dKO neurons fail to extend axons in response to Netrin suggest that *Nova1/2* most likely function cell autonomously within commissural neurons. Using quantitative RT-PCR and western blotting, we first examined the total mRNA and protein levels of *Dcc.* We found that they were not significantly altered in *Nova* dKOs, although there was a slight increase in both levels ([Figure 7---figure supplement 2A,B](#fig7s2){ref-type="fig"}).

Both human and mouse *Dcc* undergoes alternative splicing at exon 17 to give rise to *Dcc~long ~*and *Dcc~short~*, with *Dcc~long ~*containing extra 60 bp ([@bib60]; [Figure 7A](#fig7){ref-type="fig"}). Human *Dcc* undergoes additional alternative splicing in multiple regions in tumor cells ([@bib60]; [@bib29]). By RT-PCR using spinal cord tissues from both wildtype and *Nova* dKO, we found that mouse *Dcc* does not produce alterative mRNAs in these additional regions. To determine if there are previously unknown alternative splicing events in mouse *Dcc*, we amplified and sequenced overlapping cDNA fragments from CD-1 mice, and did not identify any additional alternative splicing.10.7554/eLife.14264.018Figure 7.*Nova* dKO disrupts the alternative splicing of *Dcc*.(**A**) Schematic of *Dcc* alternative splicing and the resulting isoforms. The alternative 60 bp in exon 17 is shaded grey. (**B**) *Dcc* isoform expression in nine *Nova1/2* genotypes, as measured by quantitative RT-PCR using E11.5 dorsal spinal cord. The isoform expression level is normalized to a common region in *Dcc* cDNA (total *Dcc*; see materials and methods). Note that although the changes in *Nova2* single KOs are statistically significant, the in vivo phenotype of *Nova2* KOs is not significantly different from controls (see [Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). (**C**) *Dcc* isoform expression from *Nova* embryos detected by semi-quantitative PCR that amplify both isoforms. Dorsal and ventral spinal cords are separated to distinguish commissural neurons (dorsally located) and motor neurons (ventrally located). *Nova* dKO affects *Dcc* alternative splicing in both populations. Three animals from each genotype were quantified. Data are represented as the mean ± SEM (one way ANOVA and Bonferroni post test, \*\*p\<0.001).**DOI:** [http://dx.doi.org/10.7554/eLife.14264.018](10.7554/eLife.14264.018)10.7554/eLife.14264.019Figure 7---figure supplement 1.*Nova1* and *Nova2* expression in E11.5 spinal cord detected by in situ hybridization.Both genes are expressed in interneurons at the lateral spinal cord and are highly expressed in the commissural neurons (**C**). M, motor neurons. FP, the floorplate. Scale bar, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.019](10.7554/eLife.14264.019)10.7554/eLife.14264.020Figure 7---figure supplement 2.*Nova* dKO does not affect the total level of *Dcc, Neo1*, and *Robo3* expression.(**A**) Total *Dcc* mRNA level in the spinal cords from nine genotypes of *Nova1/2,* measured by quantitative RT-PCR. There is a slight but not significant increase. (**B**) DCC protein level detected by SDS-PAGE and western blotting in *Nova* WT and dKO spinal cords. The anti-DCC (AF5) recognizes both isoforms. There is also a slight but not significant increase. (**C**) Total *Neo1* mRNA level in *Nova* WT and dKO. (**D**) Total *Robo3* mRNA level in *Nova* WT and dKO. Data are represented as the mean ± SEM (one way ANOVA and Bonferroni post test in A. Student's t-test in B, C and D. ns, not significant). For all three genes, multiple regions of the cDNAs were examined and one is shown as an example.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.020](10.7554/eLife.14264.020)10.7554/eLife.14264.021Figure 7---figure supplement 3.*Nova* dKO does not affect the alternative splicing of *Neo1, Robo3,* or *Epha5*.(**A**) *Neo1* alternative splicing in *Nova* mutants. Two alternative regions are shown, one at the homologous region to *Dcc* exon 17 and the other at *Neo1 exon* 27. Quantitative RT-PCR results are shown in the chart on the left and semi-quantitative RT-PCRs of the same regions (two animals for each genotype) are shown in the electrophoresis image on the right. (**B**) *Robo3* alternative splicing in *Nova* mutants. Six alternative regions are shown as examples and additional regions were examined. No change is seen in any region. (**C**) *Epha5* alternative splicing at exon 7 in *Nova* mutants. Three animals from each genotype were quantified. Data are normalized to WT and are represented as the mean ± SEM (Student's t-test, ns, not significant).**DOI:** [http://dx.doi.org/10.7554/eLife.14264.021](10.7554/eLife.14264.021)

Using quantitative RT-PCR, we specifically examined *Dcc* alternative splicing at exon 17 and found that it was significantly disturbed in *Nova* dKOs. *Dcc~long~* was greatly diminished, whereas *Dcc~short~* was upregulated ([Figure 7B,C](#fig7){ref-type="fig"}). In addition, the changes appear to be sensitive to *Nova1/2* gene copy number. When *Nova2* is reduced from two copies (wildtype) to one (heterozygote) and further to zero (knockout), *Dcc~long~* decreases and *Dcc~short~* increases stepwise ([Figure 7B](#fig7){ref-type="fig"}). *Nova1* KO; *Nova2* KO has the most significant changes among all genotypes. Consistently, the defects seen in *Nova1* KO; *Nova2* KO is the most severe ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). Together, these results suggest that *Nova* normally regulates *Dcc* alternative splicing by promoting *Dcc~long~* in a dose-sensitive manner. It is interesting to note that even though the changes in *Nova2* single KOs are statistically significant, no defect was seen in this genotype ([Figure 5---figure supplement 1](#fig5s1){ref-type="fig"}). This suggests that there may be a threshold for the level of *Dcc* isoforms for normal function. Alternatively, the somewhat elevated total *Dcc* expression ([Figure 7---figure supplement 2A,B](#fig7s2){ref-type="fig"}) may be able to compensate for a small disruption of activity. Consistent with our results, accompanying paper by Saito et al. also found that the alternative splicing at *Dcc *exon 17 is significantly altered in E18.5 *Nova2* KO cortex, which may contribute to additional axon guidance defects in the brain.

Several molecules have been suggested to function as Netrin co-receptors within commissural neurons, including Neogenin (NEO1), ROBO3, DSCAM, and APP ([@bib47]; [@bib59]; [@bib76]; [@bib81]). Loss of function in *Neo1*, a *Dcc* homolog and a NOVA target (see accompanying paper by Saito et al.), does not affect commissural axon outgrowth or guidance by itself, but can enhance the defects of *Dcc* KOs ([@bib76]). The ROBO3 receptor, specifically the ROBO3~A.1~ isoform, represses premature repulsion before axons reach the midline and also forms a complex with DCC to mediate Netrin attraction ([@bib9]; [@bib63]; [@bib81]). DSCAM and APP have not been shown to be required for Netrin activity in vivo ([@bib55]; [@bib59]).

Using primers that detect different regions of the cDNAs, we found that the total mRNA level of *Neo1* and *Robo3* was not affected ([Figure 7---figure supplement 2C,D](#fig7s2){ref-type="fig"}). We also examined *Neo1* alternative splicing in a homologous region to *Dcc* exon 17, and found that it was not significantly altered in the dorsal spinal cord in *Nova* dKOs ([Figure 7---figure supplement 3A](#fig7s3){ref-type="fig"}). Other alternative regions of *Neo1* ([@bib33]) were not significantly altered either ([Figure 7---figure supplement 3A](#fig7s3){ref-type="fig"}). *Robo3* pre-mRNA undergoes alternative splicing in multiple regions ([@bib6]; [@bib9]; [@bib80]). We measured the expression levels of these alternative areas, as well as the adjacent constant exons, and found no change in any of them in *Nova* dKOs compared with controls ([Figure 7---figure supplement 3B](#fig7s3){ref-type="fig"}). For further comparison, we also examined the alternative splicing of the *Epha5* receptor, which is a known NOVA target but has not been shown to play a role in the development of the dorsal spinal cord interneurons. We did not observe any change in the alternative splicing of *Epha5* exon 7 ([Figure 7---figure supplement 3C](#fig7s3){ref-type="fig"}), which is found to be altered in E18.5 *Nova2* KO cortex (see accompanying paper by Saito et al.).

Together, these results show that *Dcc* is the most likely target of *Nova1/2* that is affected within commissural neurons, while other receptors are unlikely to be responsible for the *Nova* dKO defects.

*Nova* dKOs defects can be rescued by restoring *Dcc~long ~*expression, but not by *Dcc~short ~*expression {#s2-7}
----------------------------------------------------------------------------------------------------------

If the *Nova* dKO defects are indeed caused by disturbed *Dcc* alternative splicing, with *Dcc~long~* greatly reduced, restoring *Dcc~long~* in the mutants should be able to reverse the defects. We first used the axon outgrowth assay to compare the rescuing abilities of *Dcc* isoforms. We electroporated either isoform into the spinal cords at E10.5, cultured the embryos for one day to allow exogenous protein expression, and then carried out the DSC assay. As shown above, *Nova* dKO axons fail to grow in response to Netrin-1 ([Figure 5](#fig5){ref-type="fig"}; [Figure 8A,B](#fig8){ref-type="fig"}). When *Dcc~long~* was introduced back into *Nova* dKOs, many axons extended out of the explant, whereas *Dcc~short ~*was unable to rescue the defect ([Figure 8A,B](#fig8){ref-type="fig"}). For comparison, we also overexpressed *Robo3~A.1~* in *Nova* dKOs, and found that it was unable to restore commissural axon outgrowth in *Nova* dKOs ([Figure 8A,B](#fig8){ref-type="fig"}).10.7554/eLife.14264.022Figure 8.Expression of DCC~long~, but not DCC~short~ or Robo3~A.1~, is able to rescue *Nova* dKO defects.(**A**) Dorsal spinal cord assays using *Nova* WT and dKO neurons electroporated with *gfp, Dcc~long~, Dcc~short~*, or *Robo3~A.1~*. The embryos were electroporated at E10.5 and cultured for one day to allow protein expression. DSC assays were then carried out and axons were directly visualized by GFP fluorescence. Explants were cultured for 24 hrs with 250 ng/ml Netrin-1. Only DCC~long~ expression can rescue the outgrowth defect in *Nova* dKOs. (**B**) Quantification of DSC axon length and number in **A**. Three embryos from each treatment/genotype and at least five explants from each embryo were quantified. (**C**) Transverse sections of spinal cords from *Nova* WT and dKO electroporated with *gfp, Dcc~long~, Dcc~short~*, or *Robo3~A.1~*. Only *Dcc~long~* is able to rescue the neuronal migration and axon projection defects. Bracket, ventral midline. (**D**) Quantification of phenotypes in C (see description in [Figure 1C](#fig1){ref-type="fig"}). Also see [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"} for additional quantification. (**E**) Expression of DCC~long~, DCC~short~, and ROBO3~A.1~ proteins in electroporated embryos (two embryos are shown). All three proteins were immunoprecipitated by a C-terminal HA tag and detected by western blotting. (**F**) Expression of DCC~long~, DCC~short~, and ROBO3~A.1~ proteins in dissociated dorsal spinal cord neurons, as detected by anti-HA. Data are represented as the mean ± SEM (one way ANOVA and Bonferroni post test, \*p\<0.05, \*\*p\<0.001, ns, not significant). Scale bars, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.022](10.7554/eLife.14264.022)10.7554/eLife.14264.023Figure 8---figure supplement 1.Rescue of *Nova* dKOs by *Dcc* isoforms in embryos labeled with *Atoh1-gfp*.(**A**) *Nova* dKO was electroporated with *gfp, Dcc~long~*, or *Dcc~short~*. Only *Dcc~long~* expression is able to rescue the axon projection defect. (**B**) Quantification of ventral axon projection in A. The distance from the dorsal margin of the spinal cord to the ventral most axons is compared to the total height of the spinal cord (1/2 ratio). Data are normalized to WT and are represented as the mean ± SEM (one way ANOVA and Bonferroni post test, \*p\<0.05, \*\*p\<0.001). Also see [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"} for additional quantification. Scale bar, 50 μm.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.023](10.7554/eLife.14264.023)

We then introduced *Dcc* isoforms back into cultured embryos to determine if restoring *Dcc~long~* could rescue additional defects seen in *Nova* dKOs. We electroporated the cDNAs and *Actb-gfp* into embryos at E9.5 and cultured the embryos for two days. We found that *Dcc~long~* expression in *Nova* dKOs could indeed ameliorate the neuronal migration and axon ventral projection defects ([Figure 8C,D](#fig8){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). In contrast, overexpression of *Dcc~short~*, the isoform that is abnormally upregulated, did not rescue. In fact, it exacerbated the defects, causing even fewer axons to project ventrally toward the midline ([Figure 8C,D](#fig8){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). We also overexpressed *Robo3~A.1~* in *Nova* dKOs and found that it did not have any effect on neuronal migration or axon projection ([Figure 8C,D](#fig8){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}).

To confirm the expression of the exogenous proteins, which are tagged with an HA peptide at the very C-terminus, we performed immunoprecipitation from electroporated embryos and analyzed the protein levels by SDS-PAGE and western blotting. All proteins were expressed at detectable and comparable levels ([Figure 8E](#fig8){ref-type="fig"}). We also dissociated electroporated spinal cords and examined the protein expression within GFP+ neurons. Using HA antibodies, we were able to detect all three proteins within axons ([Figure 8F](#fig8){ref-type="fig"}), showing that the proteins are properly expressed and localized. Therefore, the rescue of *Nova* dKOs only by *Dcc~long ~*suggests that the defects result directly from a loss in *Dcc* activity, in particular *Dcc~long~* activity. The inability of ROBO3~A.1~ to rescue *Nova* dKOs is consistent with the fact that *Robo3* expression and alternative splicing are not disrupted by *Nova* dKO.

Furthermore, using the *Atoh1-gfp* marker, we also found that *Dcc~long~* expression, but not *Dcc~short~*expression was able to rescue the axon projection defect in *Nova* dKOs to a large extent ([Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}).

NOVA1/2 regulate the alternative splicing of *Dcc* pre-mRNA {#s2-8}
-----------------------------------------------------------

NOVA proteins specifically recognize clusters of YCAY (Y=C/U) sequences ([@bib3]). A genome-wide study using HITS-CLIP (high-throughput sequencing of RNA isolated by crosslinking immunoprecipitation) has identified candidate target sites within *Dcc* pre-mRNA ([@bib82]). To determine if NOVA1/2 directly regulate *Dcc* alternative splicing, we carried out splicing assays using a *Dcc* minigene containing the genomic DNA between exons 16 and 17 ([Figure 9A](#fig9){ref-type="fig"}). The alternative sequence is located within exon 17 and the candidate YCAY clusters are located within exon 16, intron 16, and exon 17. We coexpressed the minigene with an empty vector or *Nova1, Nova2,* or *Ptbp2* (an unrelated splicing factor that has not been shown to affect *Dcc* alternative splicing). When the vector alone was coexpressed, we detected two RT-PCR products corresponding to *Dcc~long~* and *Dcc~short~*, respectively ([Figure 9B](#fig9){ref-type="fig"}). When *Nova1* or *Nova2* was coexpressed, *Dcc~long~* was upregulated, while *Dcc~short~* was reduced. Such changes were not observed when *Ptbp2* was coexpressed ([Figure 9B](#fig9){ref-type="fig"}). These results suggest that NOVA1/2 promote *Dcc~long~*, consistent with the observed reduction of *Dcc~long~* in *Nova* dKOs. Therefore, the in vitro splicing assays recapitulate *Dcc* alternative splicing pattern in vivo.10.7554/eLife.14264.024Figure 9.NOVA1/2 regulate *Dcc* alternative splicing.(**A**) Schematic of a *Dcc* minigene containing the genomic DNA between exons 16 and 17. The alternative sequence is shaded gray. Three candidate Nova binding sites, which are YCAY (Y=C/U) clusters, are located within exon 16, intron 16, and exon 17, respectively (dashed lines indicate the number of YCAY repeats). (**B**) Alternative splicing of wildtype and mutant minigenes. The two RT-PCR products correspond to *Dcc~long~*and *Dcc~short~*, respectively. Two additional RT-PCR products are produced by exon 17 mutations (asterisk), from utilizing two downstream cryptic splice sites. Mutations in intron 16 block NOVA1/2 from increasing *Dcc~long~.* (**C**) Alternative splicing of *Dcc* minigenes containing different numbers of mutations in intron 16. With an increasing number of mutations, NOVA1/2 gradually lose their ability to promote *Dcc~long~.***DOI:** [http://dx.doi.org/10.7554/eLife.14264.024](10.7554/eLife.14264.024)

To further determine the specificity of the effect of NOVA, we mutated the YCAY repeats to YAAY, which can no longer be recognized by NOVA ([@bib3]). The exon 16 cluster mutations did not cause any change in *Dcc* alternative splicing ([Figure 9B](#fig9){ref-type="fig"}). In contrast, when the intron 16 cluster was mutated, NOVA1 or NOVA2 could no longer promote *Dcc~long~*, indicating that these sites are essential NOVA binding sites. The exon 17 cluster is in close proximity to the splice acceptor site for *Dcc~short~*, and its mutation produced two additional RT-PCR products, generated from utilizing two downstream cryptic splice acceptors. However, NOVA1 or NOVA2 could still increase *Dcc~long~* ([Figure 9B](#fig9){ref-type="fig"}). Overall, these results show that the intron 16 cluster is the main binding site for NOVA, and the binding promotes the production of *Dcc~long~*.

The intron 16 cluster contains six YCAY repeats and is conserved in humans, with seven repeats present in human sequence. We next examined if the number of repeats could affect how effectively NOVA regulates *Dcc* alternative splicing by introducing mutations into a subset of the repeats. We found that mutations in just one repeat had little effect, but mutations in four repeats led to a partial reduction in *Dcc~long ~*when *Nova1/2* were co-expressed ([Figure 9C](#fig9){ref-type="fig"}). With five and six mutated repeats, there were even further decreases in *Dcc~long~* and corresponding increases in *Dcc~short~* ([Figure 9C](#fig9){ref-type="fig"}). These results are consistent with the dose-dependent interaction between NOVA and their RNA targets ([@bib16]; [Figure 7B](#fig7){ref-type="fig"}), and further support that these sequences are bona fide NOVA binding sites.

Discussion {#s3}
==========

Neuronal and axonal migration requires dynamic regulation of cell signaling, particularly evident as cells/axons encounter an intermediate target such as the midline of the central nervous system ([@bib17]; [@bib20]; [@bib32]). Alternative splicing has been increasingly implicated as an important means to generate temporal and spatial specific functions for guidance molecules ([@bib9]; [@bib56]). To further understand the functional significance of alternative splicing, it is important to identify the relevant splicing factors and their targets. Through an in vivo RNAi screen against RBPs, we discovered that *Nova1/2* are key regulators of both neuronal and axonal migration in the spinal cord interneurons.

We found that *Nova* deficiency reduces the migration of mitotic progenitors and differentiated interneurons in the spinal cord ([Figure 3](#fig3){ref-type="fig"},[4](#fig4){ref-type="fig"}). We observed similar defects in *Dcc* KOs, which were mostly uncharacterized before. Within the commissural interneurons, *Nova* dKO disrupts Netrin-induced axon outgrowth and ventral projection to the midline, also resembling the *Dcc* mutant ([Figure 5](#fig5){ref-type="fig"},[6](#fig6){ref-type="fig"}). The phenotypic similarity between *Nova* and *Dcc* KOs strongly suggests that *Dcc* activity is affected by *Nova* dKO. Indeed, this is confirmed by the observations that *Dcc* alternative splicing is disrupted by *Nova* dKO ([Figure 7](#fig7){ref-type="fig"}), that *Nova* dKO defects can be largely rescued in vitro and in vivo by restoring *Dcc~long ~*([Figure 8](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}), and that NOVA controls *Dcc* alternative splicing in vitro ([Figure 9](#fig9){ref-type="fig"}). Also importantly, our results show that disrupting *Dcc* alternative splicing without affecting the total *Dcc* level leads to as severe defects as *Dcc* KO, underscoring the importance of alternative splicing for the gene function.

The defects in neuronal migration, axon outgrowth, and axon guidance in *Nova* and *Dcc* KOs appear to share a common feature, which is a temporal delay. The migration is slowed but not completely blocked ([Figure 4](#fig4){ref-type="fig"}). The axon outgrowth is initially defective but becomes normal after an extended culture period ([Figure 5](#fig5){ref-type="fig"}). The axon guidance defect also appears to be somewhat alleviated at E12.5 compared to earlier stages ([Figure 6](#fig6){ref-type="fig"}). This delay could be due to an incomplete loss of the gene function in the KOs. Alternatively, NOVA proteins have been shown to regulate many target genes including *Dcc* in a temporal specific manner, generating different ratios of splice variants at different developmental stages ([@bib77]; also see accompanying paper by Saito et al.) As *Nova* deficiency changes the ratio between DCC variants, it may alter the developmental state of the neurons. Consequently, this leads to abnormal responsiveness of the neurons to the extracelluar environment and thus defects in neuronal and axonal migration.

The fact that the loss of *Dcc~long~* in *Nova* dKOs cannot be compensated by the increase in *Dcc~short ~*demonstrates that the two isoforms are functionally distinct. The two DCC isoforms differ in the FN4-FN5 linker, with both FN4 and FN5 domains interacting with Netrin ([@bib76]). A structure study of Netrin in complex with the DCC or NEO1 receptor found that DCC variants can bind to Netrin-1 with comparable affinities, but are likely to adopt distinct conformations in the ligand-receptor complex ([@bib76]). Netrin and DCC~short~ form a continuous liand:receptor complex, whereas DCC~long~ is likely to form a 2:2 ligand:receptor complex with Netrin ([@bib76]). Whether the presence of both isoforms and at different ratios can produce additional conformations of the ligand-receptor complex is completely unknown. How the architecturally distinct complexes can lead to different intracellular signaling also remains an intriguing question.

The defects seen in *Nova* dKOs could result from the loss in *Dcc~long~*, the increase in *Dcc~short~*, or the combination of both. We cannot yet distinguish between these possibilities. The rescue of *Nova* dKOs by DCC~long~, but not by DCC~short~, can also be interpreted in different ways. One possibility is that DCC~long~ is fully responsible for the gene function, whereas DCC~short~ has no activity. Another is that both isoforms are required and each has its specific activity. Only DCC~long~ can rescue *Nova* KOs because it is reduced in the mutants, while DCC~short~ is still present. Since the two *Dcc* isoforms are normally expressed at comparable levels in commissural axons at E11.5 ([Figure 7C](#fig7){ref-type="fig"}), it is likely that each isoform has its unique activity during neuronal migration and axon guidance.

*Dcc* alternative splicing was first identified using human neuroblastoma cells IMR32 ([@bib60]). Compared with normal mouse brain tissues, IMR32 expresses a decreased level of *Dcc~long ~*and an elevated level of *Dcc~short ~*([@bib60]). These changes are in the same pattern as those in *Nova* dKOs. Thus, altered *Dcc* alternative splicing may also contribute to tumor development. Allelic loss of the 18q21 region encompassing *Dcc* is identified in about 70% of primary colorectal cancers and is also found in other types of cancers ([@bib50]). It remains to be seen if altered *Dcc* alternative splicing accounts for additional cases of colorectal cancers and other cancers. Furthermore, *Dcc* plays additional roles in the nervous system, such as in dendritic growth and guidance ([@bib22]; [@bib53]; [@bib69]; [@bib73]), and in synapse formation and function ([@bib11]; [@bib23]; [@bib27]). Therefore, it is important to determine if *Dcc* alternative splicing is also important for other biological processes.

Materials and methods {#s4}
=====================

Mice {#s4-1}
----

*Nova1*, *Nova2*, and *Dcc* KOs were generated and described previously ([@bib21]; [@bib28]; [@bib31]; [@bib61]; accompanying paper by Saito et al.). All strains were outcrossed to the CD-1 strain. *Nova* double heterozygotes (dHet) were intercrossed to generate all nine genotypes used in the study.

siRNAs {#s4-2}
------

The siRNAs for candidate RNA-binding proteins were designed and synthesized by IDT (Coralville, IA). A pool of three siRNAs were used in the screen. Once phenotypes were seen, individual siRNAs were validated and the most potent siRNA was used for further phenotypic analyses. The sense sequences for the most potent *Nova* siRNAs are as follows: *Nova1* 5'tacaacctcagaccaccgttaatcctg3', *Nova2* 5'gaccatcgtgcagctccagaaggagac3', and pan*-Nova* 5'agccaccatcaagctgtctaagtccaa3'.

cDNAs {#s4-3}
-----

*Dcc, Nova1, Nova2, Ptbp2* cDNAs were cloned from wildtype CD-1 mouse spinal cords. *Robo3~A.1~*cDNA was generated previously ([@bib9]). *Actb-gfp (egfp* in pCAGGS) and *Atoh1-gfp* markers were previously described ([@bib46]; [@bib49]).

Whole embryo culture {#s4-4}
--------------------

WEC was carried out as previously described ([@bib9]). For the RNAi screen, embryos were electroporated at E9.5 with siRNAs and *gfp* into one side of the spinal cord and were cultured for 40-48 hrs. The embryos were then fixed in 4% paraformaldehyde, cryopreserved in 30% sucrose, and embedded in OCT. 20 μm transverse sections were collected and examined using fluorescent microscopy. Alternatively, openbook preparation of the spinal cord was performed and examined by fluorescent microscopy as previously described ([@bib9]).

Quantification of phentoypes {#s4-5}
----------------------------

For phenotypic quantification in all experiments, if *Nova* WT and dKO were not littermates, they were first normalized to the respective dHet littermates, and were then compared with each other. *Dcc* KOs were compared with WT littermate controls. To minimize developmental variation, we used embryos of comparable sizes and examined spinal cord tissues from the brachial level.

For quantification of cultured embryos labeled with *Actb-gfp*, neuroprogenitors in the VZ is represented as the ratio between the signal from the medial spinal cord and that from the lateral spinal cord. Axon ventral projection is represented as the ratio between the signal from axons at the ventral margin of the spinal and that from the beginning of the axon bundle. The signal intensity was measured using ImageJ (NIH, Bethesda, MD). For quantification of *Atoh1-gfp* labeled embryos, ventral axon projection is represented as the ratio between the distance from the dorsal margin of the spinal cord to the ventral most axons and the total height of the spinal cord. The distances were measured using ImageJ. In all phenotypic analyses, the defects are consistently seen in all embryos examined. The severity of defects is comparable between animals and between different sections of the same embryo. Representative images are shown in all figures. Numbers of animals and sections examined are listed in [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}.

Immunohistochemistry {#s4-6}
--------------------

IHC was carried out as previously descried ([@bib76]). Antibodies used in the study include anti-PAX3/7 (PA1-107, Thermo Fisher, Waltham, MA, raised against PAX3 and cross reacts with PAX7), anti-BARHL2 (NBP2-32013, Novus Biologicals, Littleton, CO), anti-LHX5 (AF6290, R&D, Minneapolis, MN), anti-ISL1/2 (39.4D5, DSHB, Iowa City, IA), anti-ROBO3 (rabbit polyclonal, [@bib9]), anti-TAG1 (4D7, DSHB), anti-pH3 (9701, CST, Danvers, MA), anti-Ki-67 (12202, CST), and anti-SOX2 (3728, CST).

Dorsal spinal cord explant {#s4-7}
--------------------------

DSC assay was performed as previously descried ([@bib76]). For DSC taken from embryos grown in vivo, the explants were labeled with rhodamine-phalloidin (Thermo Fisher). The outgrowth was quantified as the ratio between the signal from the axons and that from the cell bodies, after background extraction. The signal intensity was measured using ImageJ. For the rescue experiments using the dorsal spinal cord explants, embryos were electroporated with cDNAs and *gfp* at E10.5 and cultured for 24 hrs. GFP-positive DSCs were microdissected and cultured. The length and total number of GFP positive axons were quantified using ImageJ. At least three embryos from each genotype and five explants from each embryo were quantified, with genotypes and treatments blinded.

Quantitative and semi-quantitative RT-PCR {#s4-8}
-----------------------------------------

Spinal cord tissues were microdissected, and the dorsal and ventral halves were separated to distinguish the commissural and motor neuron populations. Total RNA was extracted using Trizol (Thermo Fisher), and reverse transcription was carried out using Maxima RT (Thermo Fisher). Quantitative PCR was performed using a Realplex^2^ thermocycler (Eppendorf, Hamburg, Germany). Semi-quantitative PCR was performed to generate multiple isoforms in a single reaction and compare the relative expression by electrophoresis. The cycle number used in semi-quantitative PCR was determined by quantitative PCR to obtain products during the exponential amplification phase.

In situ hybridization {#s4-9}
---------------------

ISH was performed as previously described ([@bib2]). The antisense probes were in vitro transcribed using T7 polymerase and labeled with DIG (Digoxigenin, Roche, Basel, Switzerland). Sense probes were used as negative controls. For non-fluorescent ISH, AP (alkaline phosphatase)-conjugated anti-DIG antibody (Roche) was used to detect bound antisense probes, and was visualized using colorimetric AP substrates. For FISH, HRP (horse radish peroxidase)-conjugated anti-DIG antibody (Jackson ImmunoResearch, West Grove, PA) was used and the signal was visualized using the TSA (tyramide signal amplication) system (Perkin Elmer, Waltham, MA).

Dorsal spinal cord neuron culture {#s4-10}
---------------------------------

To confirm exogenous protein expression, DSC neurons electroporated with *Dcc* or *Robo3* cDNA and *gfp* were microdissected, dissociated (0.05% trypsin, 0.5 mM EDTA), and cultured for 24 hrs in PDL (poly-D-Lysine, 100 μg/ml) coated culture dish in the culture medium (Neurobasal, 1x B27, 50 U/ml Pen/Strep, and 250 ng/ml Netrin-1). Cells were then fixed with 4% paraformaldehyde, and stained with anti-HA (3F10, Roche) and Alexa Fluor 594-conjugated secondary antibodies (Jackson ImmunoResearch).

Splicing assay {#s4-11}
--------------

*Dcc* genomic DNA that spans exons 16 and 17 (5.6 kb total) was PCR amplified from mouse spinal cords and cloned into the pDEST26 gateway vector containing a CMV promoter (Thermo Fisher). *Dcc* minigene was transfected into HEK293T cells together with the splicing factors or an empty vector at a 1:1 ratio. Cells were cultured for 48 hr and the total RNA was collected using Trizol (Thermo Fisher). Reverse transcription was carried out from a T7 promoter (present in pDEST26) using SMARTScribe reverse transcriptase (Clontech, Mountain View, CA), and semi-quantitative PCR was performed to amplify multiple isoforms. Point mutations were introduced by PCR reactions using Pfu polymerase (Agilent, Santa Clara, CA), and were confirmed by DNA sequencing. A V5 tag at the C-terminus of NOVA1, NOVA2, and PTBP2 was used to confirm protein expression using western blotting.

  **Primers used for quantitative PCR**                                                               
  --------------------------------------- ------------------------------ ---------------------------- -----------------------------
  Gene                                    Amplicon                       Forward primer               Reverse primer
  *Dcc*                                   *Dcc~long~*                    tctcattatgtaatctccttaaaagc   gggaaatcatcaagcaaaggataataa
                                          *Dcc~short~*                   tctcattatgtaatctccttaaaagc   ggtggagacatctgttatggaacga
                                          Total *Dcc* (common region)    tctcattatgtaatctccttaaaagc   ctgttatggaacgagtggtggc
  *Neo1*                                  *Neo1~long~*                   tgttattaatgctccatacactccag   ccaggtaatccttatggtgtcgt
                                          *Neo1~short~*                  cagacctcacacagtgccagatccc    ccaggtaatccttatggtgtcgt
                                          Total *Neo1* (common region)   tgccagatcccactcccat          ccaggtaatccttatggtgtcgt
  *Robo3*                                 *Robo3~A~*                     tggaggggcttacggctccc         tagcgcagcatagcgcagcc
                                          *Robo3~B~*                     acctggtcttcccccagttgct       gctcgcccctggaaaccacc
                                          *Robo3~.1~*                    ccaccacccttgccaccacc         ccaggcctcttccgcagcac
                                          *Robo3~.2~*                    ccaccacccttgccaccacc         gcaagcctccagtcccctccc
                                          *Robo3* intron 19              cctagtccctgcccctgacca        gagggactccgaggtgggtgg
                                          *Robo3* intron 20              ttggccctgctgcctacccat        tgccccaggaagctgacgga

  **Primers used for semi-quantitative PCR (amplifying multiple isoforms)**                                                
  --------------------------------------------------------------------------- --------------- ---------------------------- -------------------------
  Gene                                                                        Amplicon        Forward primer               Reverse primer
  Dcc                                                                         *Dcc* common    tctcattatgtaatctccttaaaagc   tcacagcctcatgggtaagag
  Neo1                                                                        *Neo1* common   ttggcgaaggcatccccc           ccaggtaatccttatggtgtcgt
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In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"NOVA RNA-binding proteins regulate *Dcc* alternative splicing during neuronal migration and axon guidance\" for consideration by *eLife*. Your manuscript has now been evaluated by three reviewers, one of whom is a member of the Board of Reviewing Editors and it has also been evaluated by a Senior Editor.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As you will see from the reviews, the reviewers found the paper to be interesting but identified some weaknesses that you must address before we can consider publication of the work. Some of the issues require better data analyses while others require revision of the text to consider additional interpretations. We also suggest that you read the comments on the accompanying paper from the Darnell Lab to consider some of text revisions. The separate reviews are also included at the end of this summary:

There is a main weakness that we hope you can address: If you can enhance the characterization of the anatomical phenotypes, we believe the manuscript would benefit tremendously. Currently you use fairly coarse read-outs to characterize the anatomical phenotypes. Many assessments are semi-quantitative and do not allow for an estimate of what fraction of the manipulated cells are affected. There is no doubt that the phenotypes exist and are rescued by the overexpression of the long DCC splice isoform but it remains unknown how severe the phenotypes are and whether they persist at later stages of development. Please attempt to provide more quantitative analyses and report if the phenotypes persist at later stages.

The following are additional comments that should be addressed by editing the text.

1\) The abstract of the manuscript focuses almost entirely on alternative splicing yet this aspect of the work does not begin to be addressed until late in the manuscript -- [Figure 7](#fig7){ref-type="fig"} and subsection "*Nova* dKO disrupts *Dcc* alternative splicing". The authors should consider how to balance better the content of the abstract to reflect the full body of the manuscript. Perhaps some of the data, particularly the cell migration results, can be reduced.

2\) *Nova* KO delays cell migration in the dorsal spinal cord, as does the DCC KO. It seems possible that this delay in cell migration may underlie the later-arising axon defect. For example, if axons grow out later in development they would appear to be shorter in vivo (as seen in [Figure 1](#fig1){ref-type="fig"}, and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, and [Figure 2](#fig2){ref-type="fig"}) and potentially defective due to growing in an abnormally mature spinal cord. A delay in axon outgrowth could also provide a simple explanation for the results in [Figure 5](#fig5){ref-type="fig"} where the *Nova* 1/2 dKO shows no neurite outgrowth at 24 hr defect. The authors should address this point in the manuscript.

3\) ROBO3 was examined for changes in alternative splicing in the *Nova* 1/2 KO mutant and no differences were found. But is ROBO3 a known target of *Nova*? It would be informative to include data from another receptor that is a known *Nova* target, other than DCC, to investigate here.

4\) The data can be interpreted in several different ways. The authors conclude that DCC long is required for ventral migration. An alternative view, would be that DCC~short~ antagonizes ventral migration. By inhibiting splicing the ratio of DCC~short~ to DCC~long~ increases. The data do not rule out the possibility that migration phenotype could reflect reduction in DCC~long~, an increase in DCC~short~ or both. Furthermore, normal ventral migration may require both. That is DCC~long~ and DCC~short~ may form a heterodimer and this heterodimer, and a certain level of it, may be essential for normal migration. The discussion in the other manuscript that considers the relationship between different forms of DCC and its function should be incorporated into this manuscript.

Reviewer \#1:

The manuscript investigates the function of the RNA-binding protein, *Nova*, in neuronal development in the spinal cord and reports that loss of function leads to defects in cell migration and axon guidance. The commissural neurons in the dorsal spinal cord exhibit defects in midline crossing similar to that described previously for DCC knockouts. Evidence is presented to show that *Nova* controls the splicing of DCC isoforms and that when *Nova* is knocked out, the long isoform is decreased. Expression of the long, but not the short, DCC isoform rescues the *Nova*-/- cell migration defect and the axon phenotype in vivo and in vitro. The authors conclude that splicing of DCC is important for its function in commissural neurons and that *Nova* controls this alternative splicing.

This is an interesting study that provides quite robust evidence showing that *Nova* proteins control splicing of DCC and demonstrates a key role of the long DCC isoform in controlling cell migration in the dorsal spinal cord and axon growth to the midline. Overall, the study has been well executed and the results are mostly convincing. It is perhaps surprising that alternative splicing of just one target, DCC, is identified as the key mediator of the phenotype given that *Nova* has been shown previously to have many target mRNAs. However, the evidence showing the rescue of the migration and axon phenotypes with DCC~long~ but not DCC~short~ is quite persuasive. \[Minor comments not shown.\]

Reviewer \#2:

The authors report cell migration and axon guidance phenotypes of spinal dorsal interneurons in rodent loss of function models. They conclude that the RNA binding proteins *Nova* 1 and 2 contribute to the alternative splicing regulation of the cell surface receptor DCC. Loss of *Nova1/2* or DCC result in altered migration and axon trajectory patterns of commissural interneurons. These defects can be rescued by overexpression of one DCC alternative splice variant but not by overexpression of a DCC alternative splice variant that persists in the *Nova1/2* KO embryo.

Overall, the work is interesting as it links a specific alternative splicing event in an axon guidance receptor, an RNA binding protein and potential phenotypes in a fairly intact system (embryo culture). The two main weaknesses of the study are:

1\) The authors use fairly coarse read-outs to characterize the anatomical phenotypes. Many assessments are semi-quantitative and do not allow for an estimate of what fraction of the manipulated cells are affected. There is no doubt that the phenotypes exist and are rescued by the overexpression of the long DCC splice isoform but it remains unknown how severe the phenotypes are and whether they persist at later stages of development.

2\) The other major (and probably more severe) weakness is the lack of mechanistic insight. The authors attempt to test whether the long and short DCC splice variants might differ in stability, expression, or localization and do not observe changes for ectopically expressed forms. However, it remains unclear whether the long variant indeed engages in some specific protein complexes at the cell surface. I should be noted that the authors openly discuss this issue in the manuscript and I feel that the work is an important contribution, even if the mechanism remains unclear.

\[Minor comments not shown.\]

Reviewer \#3:

In this paper, Leggere and colleagues explore the role of NOVA proteins, splicing factors highly enriched in the CNS, in regulating development of commissural neurons in the mouse spinal cord. Commissural neurons are born in the dorsal spinal cord, migrate laterally, and then ventrally to populate regions in the dorsal half of the spinal cord. These neurons send axons ventrally across the floor plate to the contralateral side of the spinal cord. Removal of both NOVA1 and NOVA2, first shown using RNAi and then through traditional mutations, disrupts the development of these neurons. Data are presented that these neurons differentiate normally, as assessed by various markers, but they show abnormalities in cell migration (both laterally and ventrally) and in axon guidance to the ventral midline. As these phenotypes are similar to DCC loss-of-function mutations, the authors sought to explore the relationship between NOVA1/2 and DCC function. DCC is a receptor for netrin; netrin is expressed in the ventral half of the spinal cord and plays an important role in regulating the ventral migration of commissural neurons and the guidance of the growth cones to the floor plate.

The authors demonstrate that NOVA1/2 regulates alternative splicing of DCC. In the DCC pre-mRNA there are two alternative acceptor sites downstream of exon 16. The use of 5\'-site generates a protein with an insert of 20AA longer than the protein in the downstream site. These are referred to as DCC~long~ and DCC~short~, respectively. The authors demonstrate that the NOVA1/2 phenotype can be rescued by expression of DCC~long~ but not DCC~short~. Using a cell-culture based splicing assay, they showed that NOVA1/2 regulates this splice and does so through specific interactions with YCAY sites (canonical NOVA1/2 recognition sequences) within the intron separating exon 15 and 16.

The paper is clearly written and the data in the figures are easy to follow. The data can be interpreted in several different ways. The authors conclude that DCC long is required for ventral migration. An alternative view, would be that DCC~short~ antagonizes ventral migration. By inhibiting splicing the ratio of DCC~short~ to DCC~long~ increases. The data do not rule out the possibility that migration phenotype could reflect reduction in DCC~long~, an increase in DCC~short~ or both. Furthermore, normal ventral migration may require both. That is DCC~long~ and DCC~short~ may form a heterodimer and this heterodimer, and a certain level of it, may be essential for normal migration. The discussion in the other manuscript that considers the relationship between different forms of DCC and its function should be incorporated into this manuscript.

The paper is appropriate for *eLife*.

10.7554/eLife.14264.028

Author response

There is a main weakness that we hope you can address: If you can enhance the characterization of the anatomical phenotypes, we believe the manuscript would benefit tremendously. Currently you use fairly coarse read-outs to characterize the anatomical phenotypes. Many assessments are semi-quantitative and do not allow for an estimate of what fraction of the manipulated cells are affected. There is no doubt that the phenotypes exist and are rescued by the overexpression of the long DCC splice isoform but it remains unknown how severe the phenotypes are and whether they persist at later stages of development. Please attempt to provide more quantitative analyses and report if the phenotypes persist at later stages.

We think this comment refers to the quantification of the cultured embryos. The phenotypic analyses and quantifications of knockout embryos and of neuronal explants were carried out using previously published methods. It is technically challenging to assess the phenotypes in cultured embryos labeled with *Actb-gfp (βactin-gfp*). The GFP is expressed throughout the cell bodies and the neurites and the neurons are closely positioned, making it difficult to discern individual neurons. We thus compared the overall signal from the ventricular zone with that from the lateral spinal cord to assess neuronal migration. It is also difficult to count GFP+ axons as they form bundles, and to measure the axon length as the cell bodies are positioned at different dorsoventral level. With that said, we have performed the following quantifications to improve our data.

1\) We have now quantified the ventral projection of the commissural axons using embryos labeled with the Atoh1-gfp (Math1-gfp) marker. Atoh1 is expressed by neurons born at the dorsal margin of the spinal cord, whose axons extend across the whole spinal cord to the ventral midline. We measured the distance from the dorsal margin of the spinal cord to the ventral most GFP+ axons and the total height of the spinal cord. The ratio between the two represents the portion of the spinal cord that the leading axons have traversed ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Consistent with the quantification using Actb-gfp, both Nova and Dcc KOs display a significant decrease in the ventral axon projection toward the midline. And Dcc~long~ is able to restore the ventral projection in Nova KOs (quantification now included in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}, and [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}).

2\) We have also included the number of embryos and sections analyzed and the fraction of sections where we observed the phenotypes in neuronal migration and axon guidance ([Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). We would like to emphasize that in all phenotypic analyses, the defects are consistently seen in all embryos examined. The severity of defects is comparable between animals and between different sections of the same embryo. Representative images are shown in all figures.

To address if the phenotypes persist at later stages, we have performed the following experiments.

1\) We were able to culture some mouse embryos until the equivalent stage of E12 (half a day older than those shown in [Figures 1](#fig1){ref-type="fig"} and [8](#fig8){ref-type="fig"}). It is technically difficult to grow the embryos any longer due to reduced survival. In the older embryos, the cell migration defect appeared to be slightly improved in *Nova* KOs, but there are still fewer axons than in controls . We did not include the data in the manuscript as we feel that the data using the KO embryos is more quantitative (see below).

2\) Using knockout embryos, we examined axon guidance at a later stage and the data is incorporated into [Figure 6A](#fig6){ref-type="fig"} (ROBO3 staining at E12.5). We found that at E12.5, the axon guidance defect in both *Nova* and *Dcc* KOs is still present, but is somewhat weaker than at earlier stages. Examination of even later stages is difficult, as the ROBO3 and TAG-1 markers become downregulated after E12.5 and E11.5, respectively. We have also provided further discussion on the temporal profile of the defects in the manuscript.10.7554/eLife.14264.025Author response image 1.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.025](10.7554/eLife.14264.025)

In a previous study where we used the embryo culture to determine the function of different Robo3 receptor isoforms (Chen et al., Neuron, 2008), we assessed what fraction of the manipulated cells is affected. We found that the exogenously expressed ROBO3~A.1~ protein mostly overlaps with the GFP marker and ROBO3~A.1~ expression is able to rescue the midline crossing defect in Robo3 KOs to a large extent. We estimated that around 80% of Robo3 KO axons that express Robo3~A.1~ are able to cross the midline, whereas no axon expressing GFP alone can cross.10.7554/eLife.14264.026Author response image 2.**DOI:** [http://dx.doi.org/10.7554/eLife.14264.026](10.7554/eLife.14264.026)

Using the same approach, we attempted to assess what fraction of neurons that exogenously express DCC is affected in this study. However, due to the presence of endogenous DCC in *Nova* KOs, we were unable to specifically detect the exogenous protein using anti-DCC. The exogenous DCC is tagged with HA at the C-terminus. Although we could detect the HA tag in dissociated neurons ([Figure 8F](#fig8){ref-type="fig"}), we were unable to detect any signal in tissue sections. However, given that the rescue of *Nova* dKO by *Dcc*~long~ is observed in all animals and in all sections examined, and that the rescue is to a large degree ([Figure 8](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}), we think most manipulated cells are affected, similar to what we have observed before in the Robo3 study.

The following are additional comments that should be addressed by editing the text.

1\) The abstract of the manuscript focuses almost entirely on alternative splicing yet this aspect of the work does not begin to be addressed until late in the manuscript -- [Figure 7](#fig7){ref-type="fig"} and subsection "Nova dKO disrupts Dcc alternative splicing". The authors should consider how to balance better the content of the abstract to reflect the full body of the manuscript. Perhaps some of the data, particularly the cell migration results, can be reduced.

We have modified the abstract to better reflect the overall findings of the study. We have also reduced the text describing the cell migration results.

2\) Nova KO delays cell migration in the dorsal spinal cord, as does the DCC KO. It seems possible that this delay in cell migration may underlie the later-arising axon defect. For example, if axons grow out later in development they would appear to be shorter in vivo (as seen in [Figure 1](#fig1){ref-type="fig"}, and [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, and [Figure 2](#fig2){ref-type="fig"}) and potentially defective due to growing in an abnormally mature spinal cord. A delay in axon outgrowth could also provide a simple explanation for the results in [Figure 5](#fig5){ref-type="fig"} where the Nova 1/2 dKO shows no neurite outgrowth at 24 hr defect. The authors should address this point in the manuscript.

We agree that the cell migration and axon outgrowth/guidance defects seen in *Nova* and *Dcc* KOs may share a common underlying mechanism, which is a temporal delay. Per reviewer 2' suggestion, we have now included axon guidance data from a later stage ([Figure 6A](#fig6){ref-type="fig"}, ROBO3 staining at E12.5). We found that at E12.5, the axon guidance defect in both *Nova* and *Dcc* KOs is still present, but is somewhat weaker than at earlier stages. Together, these data suggest that a temporal delay may underlie the defects in both cell migration and axon guidance. We have now included further discussion to address this point.

3\) ROBO3 was examined for changes in alternative splicing in the Nova 1/2 KO mutant and no differences were found. But is ROBO3 a known target of Nova? It would be informative to include data from another receptor that is a known Nova target, other than DCC, to investigate here.

Robo3 has not been shown to be a NOVA target. A previous transcriptome-wide HITS-CLIP from the Darnell group did not identify any candidate NOVA binding sites within Robo3 (Zhang et al., Science, 2010). However, due to the low expression level of Robo3 in the examined tissue (P0 brain), the result does not rule out Robo3 as a potential target (personal communication with R.B. Darnell). We examined Robo3 as it functions as a coreceptor with *Dcc* and is known to undergo alternative splicing.

Besides *Dcc* and Robo3, we also examined *Neo1*, which is a *Dcc* homolog and a known NOVA target. We have edited the text to make this point clear. We found that its alternative splicing at exons 18 and 27 was not significantly altered by *Nova* KO in the dorsal spinal cord ([Figure 7---figure supplement 3A](#fig7s3){ref-type="fig"}).

To further address the reviewer's question, we have now examined the *Epha5* receptor ([Figure 7---figure supplement 3C](#fig7s3){ref-type="fig"}). *Epha5* is a known NOVA target but has not been shown to play a role in the development of the spinal interneurons. We found no change in *Epha5* alternative splicing at exon 7 in the dorsal spinal cord.

Interestingly, the accompanying paper by Saito et al. shows that the alternative splicing of *Neo1* exon 27 and *Epha5* exon 7 is significantly altered in E18.5 *Nova2* KO cortex. The distinct observations between E11.5 dorsal spinal cord and E18.5 cortex show that NOVA functions in a temporospatial specific manner.

4\) The data can be interpreted in several different ways. The authors conclude that DCC~long~ is required for ventral migration. An alternative view, would be that DCC~short~ antagonizes ventral migration. By inhibiting splicing the ratio of DCC~short~ to DCC~long~ increases. The data do not rule out the possibility that migration phenotype could reflect reduction in DCC~long~, an increase in DCC~short~ or both. Furthermore, normal ventral migration may require both. That is DCC~long~ and DCC~short~ may form a heterodimer and this heterodimer, and a certain level of it, may be essential for normal migration. The discussion in the other manuscript that considers the relationship between different forms of DCC and its function should be incorporated into this manuscript.

We fully agree that there are several alternative models on DCC isoform functions. Our data does not yet allow us to distinguish between the different possibilities outlined by the reviewer. We have now included more thorough discussion on the possible interpretations of our results.

Reviewer \#2:

The authors report cell migration and axon guidance phenotypes of spinal dorsal interneurons in rodent loss of function models. They conclude that the RNA binding proteins Nova 1 and 2 contribute to the alternative splicing regulation of the cell surface receptor DCC. Loss of Nova1/2 or DCC result in altered migration and axon trajectory patterns of commissural interneurons. These defects can be rescued by overexpression of one DCC alternative splice variant but not by overexpression of a DCC alternative splice variant that persists in the Nova1/2 KO embryo.

Overall, the work is interesting as it links a specific alternative splicing event in an axon guidance receptor, an RNA binding protein and potential phenotypes in a fairly intact system (embryo culture). The two main weaknesses of the study are:

1\) The authors use fairly coarse read-outs to characterize the anatomical phenotypes. Many assessments are semi-quantitative and do not allow for an estimate of what fraction of the manipulated cells are affected. There is no doubt that the phenotypes exist and are rescued by the overexpression of the long DCC splice isoform but it remains unknown how severe the phenotypes are and whether they persist at later stages of development.

We think this comment refers to the quantification of the cultured embryos. The phenotypic analyses and quantifications of knockout embryos and of neuronal explants were carried out using previously published methods. It is technically challenging to assess the phenotypes in cultured embryos labeled with *Actb-gfp (βactin-gfp*). The GFP is expressed throughout the cell bodies and the neurites and the neurons are closely positioned, making it difficult to discern individual neurons. We thus compared the overall signal from the ventricular zone with that from the lateral spinal cord to assess neuronal migration. It is also difficult to count GFP+ axons as they form bundles, and to measure the axon length as the cell bodies are positioned at different dorsoventral level. With that said, we have performed the following quantifications to improve our data.

1\) We have now quantified the ventral projection of the commissural axons using embryos labeled with the *Atoh1-gfp (Math1-gfp*) marker. *Atoh1* is expressed by neurons born at the dorsal margin of the spinal cord, whose axons extend across the whole spinal cord to the ventral midline. We measured the distance from the dorsal margin of the spinal cord to the ventral most GFP+ axons and the total height of the spinal cord. The ratio between the two represents the portion of the spinal cord that the leading axons have traversed ([Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}). Consistent with the quantification using *Actb-gfp*, both *Nova* and *Dcc* KOs display a significant decrease in the ventral axon projection toward the midline. And *Dcc*~long~ is able to restore the ventral projection in *Nova* KOs (quantification now included in [Figure 1---figure supplement 2](#fig1s2){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}, and [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}).

2\) We have also included the number of embryos and sections analyzed and the fraction of sections where we observed the phenotypes in neuronal migration and axon guidance ([Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}). We would like to emphasize that in all phenotypic analyses, the defects are consistently seen in all embryos examined. The severity of defects is comparable between animals and between different sections of the same embryo. Representative images are shown in all figures.

To address if the phenotypes persist at later stages, we have performed the following experiments.

1\) We were able to culture some mouse embryos until the equivalent stage of E12 (half a day older than those shown in [Figures 1](#fig1){ref-type="fig"} and [8](#fig8){ref-type="fig"}). It is technically difficult to grow the embryos any longer due to reduced survival. In the older embryos, the cell migration defect appeared to be slightly improved in *Nova* KOs, but there are still fewer axons than in controls. We did not include the data in the manuscript as we feel that the data using the KO embryos is more quantitative (see below).

2\) Using knockout embryos, we examined axon guidance at a later stage and the data is incorporated into [Figure 6A](#fig6){ref-type="fig"} (ROBO3 staining at E12.5). We found that at E12.5, the axon guidance defect in both *Nova* and *Dcc* KOs is still present, but is somewhat weaker than at earlier stages. Examination of even later stages is difficult, as the ROBO3 and TAG-1 markers become downregulated after E12.5 and E11.5, respectively. We have also provided further discussion on the temporal profile of the defects in the manuscript.

In a previous study where we used the embryo culture to determine the function of different Robo3 receptor isoforms (Chen et al., Neuron, 2008), we assessed what fraction of the manipulated cells is affected. We found that the exogenously expressed ROBO3~A.1~ protein mostly overlaps with the GFP marker and ROBO3~A.1~ expression is able to rescue the midline crossing defect in Robo3 KOs to a large extent. We estimated that around 80% of Robo3 KO axons that express Robo3~A.1~ are able to cross the midline, whereas no axon expressing GFP alone can cross.

Using the same approach, we attempted to assess what fraction of neurons that exogenously express DCC is affected in this study. However, due to the presence of endogenous DCC in *Nova* KOs, we were unable to specifically detect the exogenous protein using anti-DCC. The exogenous DCC is tagged with HA at the C-terminus. Although we could detect the HA tag in dissociated neurons ([Figure 8F](#fig8){ref-type="fig"}), we were unable to detect any signal in tissue sections. However, given that the rescue of *Nova* dKO by *Dcc*~long~ is observed in all animals and in all sections examined, and that the rescue is to a large degree ([Figure 8](#fig8){ref-type="fig"}, [Figure 8---figure supplement 1](#fig8s1){ref-type="fig"}, [Figure 1---source data 1](#SD1-data){ref-type="supplementary-material"}), we think most manipulated cells are affected, similar to what we have observed before in the Robo3 study.

2\) The other major (and probably more severe) weakness is the lack of mechanistic insight. The authors attempt to test whether the long and short DCC splice variants might differ in stability, expression, or localization and do not observe changes for ectopically expressed forms. However, it remains unclear whether the long variant indeed engages in some specific protein complexes at the cell surface. I should be noted that the authors openly discuss this issue in the manuscript and I feel that the work is an important contribution, even if the mechanism remains unclear.

We agree that our study does not yet address the mechanism underlying the distinct activities of DCC isoforms. There are many possibilities to be examined. This study revealed the functional importance of *Dcc* alternative splicing and identified the relevant splicing factor, which would be the first step in determining how each DCC variant contributes to the gene function during cell migration and axon guidance.

Reviewer \#3:

\[...\] The paper is clearly written and the data in the figures are easy to follow. The data can be interpreted in several different ways. The authors conclude that DCC long is required for ventral migration. An alternative view, would be that DCC~short~ antagonizes ventral migration. By inhibiting splicing the ratio of DCC~short~ to DCC~long~ increases. The data do not rule out the possibility that migration phenotype could reflect reduction in DCC~long~, an increase in DCC~short~ or both. Furthermore, normal ventral migration may require both. That is DCC~long~ and DCC~short~ may form a heterodimer and this heterodimer, and a certain level of it, may be essential for normal migration. The discussion in the other manuscript that considers the relationship between different forms of DCC and its function should be incorporated into this manuscript.

The paper is appropriate for eLife.

We fully agree that there are several alternative models on DCC isoform functions. Our data does not yet allow us to distinguish between the different possibilities outlined by the reviewer. We have now included more thorough discussion on the possible interpretations of our results.
